Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
June 28 2018 - 5:07PM
Edgar (US Regulatory)
Filed by Akebia Therapeutics, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
Commission File No.:
001-36352
Subject Company: Keryx Biopahrmaceuticals, Inc.
Commission File No.:
000-30929
Date: June 28, 2018
The following are social
media communications by Akebia Therapeutics, Inc. (Akebia) that discuss the proposed merger of Akebia and Keryx Biopharmaceuticals, Inc.
Social Media Communications by
Akebia
The following communication was posted on June 28, 2018 by Akebia on Twitter:
Twitter: https://twitter.com/akebiatx
The following communication was posted on June 28, 2018 by Akebia at www.linkedin.com:
LinkedIn: https://www.linkedin.com/company/5020330/admin/updates/
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2023 to Aug 2024